Enrolling Pregnant Women: Issues in Clinical Research

Women's Health Issues

Volumn 23, Issue 1, 2013, Pages

  Blehar, Mary C ^a   Spong, Catherine ^b   Grady, Christine ^a   Goldkind, Sara F ^c   Sahin, Leyla ^c   Clayton, Janine A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHILD HEALTH; CLINICAL RESEARCH; EVIDENCE BASED PRACTICE; GOVERNMENT REGULATION; HEALTH CARE NEED; HEALTH CARE PLANNING; HEALTH STATUS; HUMAN; INFORMATION PROCESSING; INSTITUTIONAL REVIEW; LEGAL ASPECT; MATERNAL CARE; MEDICAL ETHICS; NATIONAL HEALTH ORGANIZATION; POPULATION RESEARCH; PREGNANT WOMAN; PROFESSIONAL STANDARD; REGISTRATION; VULNERABLE POPULATION; WOMEN'S HEALTH; WORKSHOP;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; ETHICS COMMITTEES, RESEARCH; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); PATIENT SELECTION; PREGNANCY; PREGNANT WOMEN; RESEARCH SUBJECTS; UNITED STATES; VULNERABLE POPULATIONS;

EID: 84872225973     PISSN: 10493867     EISSN: 18784321     Source Type: Journal    
DOI: 10.1016/j.whi.2012.10.003     Document Type: Article

References (30)

1. American College of Obstetricians and Gynecologists Committee of Obstetric Practice ACOG Committee Opinion number 268, Management of asymptomatic pregnant or lactating women exposed to anthrax. Obstetrics and Gynecology 2002, 99:366-368.
2. Andrade S.E., Gurwitz J.H., Davis R.L., Chan K.A., Finkelstein J.A., Fortman K., et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004, 191(2):398-407.
3. Andrew M.A., Easterling T.R., Carr D.B., Shen D., Buchanan M.L., Rutherford T., et al. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clinical Pharmacology and Therapeutics 2007, 81:547-556.
4. Anway M.D., Cupp A.S., Uzumcu M., Skinner M.K. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 2005, 308:1466-1469.
5. Chambers C.D., Polifka J.E., Friedman J.M. Drug safety in pregnant women and their babies: ignorance not bliss. Clinical Pharmacology and Therapeutics 2008, 83(1):181-183.
6. Crews D., Gore A.C., Hsu T.S., Dangleben N.L., Spinetta M., Schallert T., Anway M.D., et al. Transgenerational epigenetic imprints on mate preference. Proceedings of the National Academy of Science of the United States of America 2007, 104:5942-5946.
7. De Boo H.A., Harding J.E. The developmental origins of adult disease (Barker) hypothesis. Australian and New Zealand Journal of Obstetrics and Gynaecology 2006, 46:4-14.
8. Foulkes M., Grady C., Spong C.Y., Bates A., Clayton J.A. Clinical research enrolling pregnant women. A workshop summary. Journal of Women's Health 2011, 20:1429-1432.
9. Goldkind S.F., Sahin L., Gallauresi B. Enrolling pregnant women in research: Lessons from the H1N1 influenza pandemic. New England Journal of Medicine 2010, 326:2241-2243.
10. Kimberly M.B., Hoehn K.S., Feudtner C., Nelson R.M., Schreiner M. Variation in standards of research compensation and child assent practices: A comparison of 69 institutional review board-approved informed permission and assent forms for 3 multicenter pediatric clinical trials. Pediatrics 2006, 117:1706-1711.
11. Levine, R. J. (2011) IRB perspective on inclusion of pregnant women in clinical research. In: Issues in clinical research: Enrolling pregnant. A workshop report. Available from http://orwh.od.nih.gov/resources/policyreports/pdf/ORWH-EPW-Report-2010.pdf.
12. Little B.B. Pharmacokinetics during pregnancy: Evidence-based maternal dose formulation. Obstetrics and Gynecology 1999, 93:858-868.
13. Lyerly A.D., Little M.O., Faden R.R. Reframing the framework: toward fair inclusion of pregnant women as participants in research. American Journal of Bioethics 2011, 11(5):50-52.
14. Lyerly A.D., Little M.O., Faden R.R. The second wave: Toward responsible inclusion of pregnant women in research. International Journal of Feminist Approaches to Bioethics 2008, 1:5-22.
15. Macklin R. The art of medicine: Enrolling pregnant women in biomedical research. Lancet, 2010, 375(9715):632-633.
16. McCullough L.B., Coverdale J.H., Chervenak F.A. A comprehensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women. American Journal of Obstetrics and Gynecology 2005, 193:901-907.
17. Markens S., Browner C.H., Press N. Feeding the fetus: On interrogating the notion of maternal-fetal conflict. Feminist Studies 1997, 23:351-372.
18. Women and health research: Ethical and legal issues of including women in clinical studies 1994, Institute of Medicine, Washington, DC. A.C. Mastroianni, R.R. Faden, D.D. Federman (Eds.).
19. Ray J.G., Vermeulen M.J., Schull M.J., Redelmeier D.A. Cardiovascular health after maternal placental syndromes (CHAMPS): Population-based retrospective cohort study. Lancet 2005, 366(9499):1797-1803.
20. Shah S., Whittle A., Wilfond B., Gensler G., Wendler D. How do institutional review boards apply the federal risk and benefit standards for pediatric research?. Journal of the American Medical Association 2004, 291:476-482.
21. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). (2004a). Guidance for industry: Pharmacokinetics in pregnancy-Study design, data analysis, and impact on dosing and labeling. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072133.pdf.
22. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). (2004b). Guidance for industry: Establishing pregnancy exposure registries. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071639.pdf.
23. U.S. Department of Health and Human Services 2005 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). (2005). Guidance for industry. Clinical lactation studies: Study design, data analysis, and recommendations for labeling. Available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127505.pdf.
24. U.S.Department of Health and Human Services (DHHS), Public Health Service, National Institutes of Health Agenda for research on women's health for the 21st century. A report of the Task Force on the NIH Women's Health Research Agenda for the 21st Century, volume 1 1999, Author, Washington, DC.
25. U.S.Department of Health and Human Services (DHHS), National Institutes of Health.Office of Research on Women's Health Moving into the future with new dimensions and strategies: A vision for 2020 for women's health research 2010, Author, Washington, DC.
26. U.S. Food and Drug Administration. (2011). Pregnancy and lactation labeling. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm.
27. U.S. Food and Drug Administration. (2012a). Guidance agenda: new & revised draft guidances CDER is planning to publish during calendar year 2012. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm314767.htm.
28. U.S. Food and Drug Administration. (2012b). list of pregnancy exposure registries. Available at: http://www.fda.gov/scienceresearch/specialtopics/womenshealthresearch/ucm134848.htm.
29. Whittle A., Shah S., Wilfond B., Gensler G., Wendler D. Institutional review board practices regarding assent in pediatric research. Pediatrics 2004, 113:1747-1752.
30. Wood S.F., Blehar M.C., Mauery R. Policy implications of a new National Institutes of Health agenda for women's health research, 2010-2020. Women's Health Issues 2011, 21:99-103.